Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade

BRAF-targeted therapy results in objective responses in the majority of patients, however the responses are short-lived (~6 months). In contrast, treatment with immune checkpoint inhibitors results in a lower response rate, but the responses tend to be more durable. BRAF inhibition results in a more...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Cooper, Zachary A., Juneja, Vikram R., Sage, Peter T., Frederick, Dennie T., Piris, Adriano, Mitra, Devarati, Lo, Jennifer A., Hodi, F. Stephen, Freeman, Gordon J., Bosenberg, Marcus W., McMahon, Martin, Flaherty, Keith T., Fisher, David E., Sharpe, Arlene H., Wargo, Jennifer A.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2014
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4097121/
https://ncbi.nlm.nih.gov/pubmed/24903021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-13-0215
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים